Symposien

Next Generation Antibodies – Sharpened Tools

Saal: Terrassensaal A

Since the Nobel Prize honoured technology to produce monoclonal antibodies was invented in the 1970s, monoclonal antibodies have revolutionized medicine. And the evolution continues. Traditional monoclonal antibodies can now be modified to do their job in therapy even better. So called next generation antibody therapeutics include e. g. antibody–drug conjugates (ADCs), bispecific antibodies, engineered antibodies, antibody fragments and nanobodies. This symposium highlights some examples of promising candidates.

Chair

Prof. Dr. Ralf Huss

Prof. Dr. Ralf Huss

BioM Biotech Cluster Development GmbH

Vorträge

Dr. Jan Schmidt-Brand

Dr. Jan Schmidt-Brand

Heidelberg Pharma AG

ATACs: A Unique New Mode of Action to Fight Cancer

Dr. Thorsten Schmidt

Dr. Thorsten Schmidt

Sanofi-Aventis Deutschland GmbH

High Throughput and Computational Engineering Technologies for the Development of Multispecific Protein Therapeutics

Dr. Dominik Schumacher

Dr. Dominik Schumacher

Tubulis GmbH

Reimagining Antibody Drug Conjugates